• Cy5-UTP: Advanced RNA Labeling for In Vitro Transcription Su

  2026-06-22

  Cy5-UTP (Cyanine 5-UTP) unlocks highly sensitive, direct RNA probe visualization in applications from FISH to dual-color arrays. Its robust incorporation and streamlined workflow minimize troubleshooting, enabling researchers to confidently dissect RNA-protein interactions and complex regulatory networks.

• Indazole/Indole Glucagon Receptor Antagonists: Synthesis and

  2026-06-21

  This study introduces a novel series of potent indazole- and indole-based glucagon receptor antagonists as potential therapeutics for type 2 diabetes mellitus. By leveraging innovative amide bond formation strategies, the researchers achieved efficient synthesis and demonstrated promising in vitro and in vivo efficacy, offering new directions for metabolic disease drug discovery.

• Deferasirox: Oral Iron Chelator for Advanced Experimental Wo

  2026-06-20

  Deferasirox is revolutionizing how researchers target iron metabolism, from classic iron overload models to cutting-edge cancer studies. This guide translates recent mechanistic advances into actionable protocols, troubleshooting, and strategic advantages—positioning APExBIO’s Deferasirox as a foundational tool for translational and discovery research.

• Practical Use of Oligo (dT) 25 Beads for Eukaryotic mRNA Iso

  2026-06-19

  Oligo (dT) 25 Beads address the challenge of isolating high-purity, intact eukaryotic mRNA from complex biological samples by leveraging selective polyA tail binding. This product should be used when downstream applications—such as RT-PCR or cDNA library construction—require mRNA of high integrity, but is not suitable in workflows where non-polyadenylated RNA species are desired.

• Propidium Iodide: DNA Intercalating Dye for Cell Analysis Ex

  2026-06-19

  Propidium iodide empowers researchers to pinpoint cell viability, apoptosis, and cell cycle changes with quantitative precision. Discover how APExBIO’s PI (B7758) streamlines workflows, boosts reproducibility, and supports advanced applications in reproductive biology and disease modeling.

• Malate (SKU M1314): Optimizing TCA Cycle Assays in the Lab

  2026-06-18

  This article explores how malate (SKU M1314), also known as (S)-2-hydroxysuccinic acid, addresses core challenges in cell viability and metabolic flux research. Scenario-driven Q&A blocks provide evidence-based guidance for protocol optimization, data interpretation, and reliable product selection, with direct links to performance data and peer-reviewed literature. Researchers will find actionable strategies for maximizing reproducibility and sensitivity when using malate in TCA cycle and immunometabolism studies.

• Propidium Iodide: Precision DNA Intercalating Dye for Cell A

  2026-06-18

  Propidium iodide empowers researchers with selective, high-contrast detection of cell viability, apoptosis, and cell cycle phase—enabling advanced, reproducible insights in immunology and oncology. This article translates the latest research and expert workflows into actionable, troubleshooting-rich protocols for maximizing PI’s value in multiparametric assays.

• BAPTA Calcium Chelator: Mechanistic Insights for Apoptosis A

  2026-06-17

  Explore the advanced mechanistic role of BAPTA as a calcium chelator in apoptosis research, highlighting assay-critical insights from recent environmental toxicology findings. This article uniquely bridges molecular mechanisms with experimental design, empowering informed calcium signaling studies.

• Enzyme and Transporter-Mediated DDI Risks in 2022 FDA Drugs

  2026-06-17

  This article analyzes a recent comprehensive review of enzyme- and transporter-mediated drug-drug interaction (DDI) risks among small molecule drugs approved by the FDA in 2022. The study provides mechanistic insights and clinical recommendations, with specific emphasis on the pharmacokinetic interaction profile of Oteseconazole (VT-1161) among other agents. These findings inform safer polypharmacy and antifungal research strategies.

• Recombinant Annexin V Inhibits Thrombin Formation via Endoth

  2026-06-16

  This study rigorously quantifies how recombinant annexin V binds to phosphatidylserine on human endothelial cells and directly inhibits thrombin formation. By correlating binding parameters with inhibition of key coagulation enzyme complexes, the work advances mechanistic understanding of annexin V as an antithrombotic agent and phosphatidylserine binding protein, with implications for apoptosis and cell death research.

• mSWI/SNF ATPase Degraders and Overcoming PROTAC Resistance i

  2026-06-16

  This study presents the development of AU-24118, the first orally bioavailable dual mSWI/SNF ATPase PROTAC degrader, demonstrating robust efficacy against castration-resistant prostate cancer. Mechanistic insights reveal that acquired resistance can arise via SMARCA4 mutations or ABCB1 overexpression, the latter of which is reversible with P-glycoprotein inhibition strategies.

• Cell Cycle Assay Kit: Precision Analysis of Cell Cycle Phase

  2026-06-15

  Unlock unparalleled resolution of G0/G1, S, and G2/M cell cycle phases and sub-G1 apoptosis with APExBIO’s Cell Cycle Assay Kit (K2263). This workflow-driven guide reveals how cutting-edge PI/RNase A staining and robust troubleshooting enable cancer research and translational studies to move beyond standard cell proliferation assays.

• Cy5-UTP: Illuminating RNA Regulation for Translational Advan

  2026-06-15

  Explore how Cy5-UTP (Cyanine 5-UTP) transforms mechanistic insight into actionable translational strategy. Drawing on cutting-edge research into U3 snoRNA and DDX21, and leveraging APExBIO’s robust reagent, this article integrates mechanistic, protocol, and strategic perspectives for next-generation RNA labeling and visualization.

• 0.4% Trypan Blue Solution: Practical Guide for Cell Viabilit

  2026-06-14

  0.4% Trypan Blue Solution is a membrane-impermeable azo dye for cell staining, enabling direct live/dead cell discrimination in viability and cytotoxicity assays. It is not intended for diagnostic or clinical use. Researchers should apply it strictly within research protocols focused on cell viability measurement and not for applications requiring medical validation.

• JNJ-26481585 (Quisinostat): Epigenetic Precision in TRIM21-D

  2026-06-13

  Explore how JNJ-26481585 (Quisinostat) redefines HDAC inhibitor applications in cancer research through targeted modulation of TRIM21 and advanced epigenetic strategies. This article offers a unique, in-depth analysis for translational oncology workflows.

461 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page